---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211534"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:40:05.747693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics initiates registrational cohorts after positive Phase 1/2 DELIVER data; leadership changes

## Summary
- DYNE-251 (20 mg/kg Q4W) showed mean absolute dystrophin 3.71% of normal (unadjusted), >10x eteplirsen's 0.3% (cross-trial caution).
- Functional improvement in NSAA, SV95C (met EMA MCID), 10-MWR, Time to Rise from Floor; 10 mg/kg cohort improved from 6 to 12 months.
- Safety: favorable profile; no related SAEs except two at 40 mg/kg (resolved); >675 doses, >50 patient-years follow-up.
- Leadership: CMO Wildon Farwell resigned; hired Doug Kerr as CMO, Johanna Friedl-Naderer as CCO, Lucia Celona as CHRO; CBO and COO also resigning.
- Plans to update path to registration for DYNE-251 and DYNE-101 by end of 2024; ACHIEVE trial safety favorable up to 6.8 mg/kg Q8W.

## SEC filing metadata
- accession: 0001193125-24-211534
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/0001193125-24-211534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/d786894d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211534
- JSON: https://secwatch.observer/filing/0001193125-24-211534.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211534.txt

## Key facts
- Executive change
  Jonathan McNeill, M.D. resigned as Chief Business Officer at Dyne Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Business Officer
  source text: Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/0001193125-24-211534-index.htm
- Executive change
  Susanna High resigned as Chief Operating Officer at Dyne Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: Jonathan McNeill, M.D., the Company’s Chief Business Officer, and Susanna High, the Company’s Chief Operating Officer, each notified the Company of their intention to resign their employment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312524211534/0001193125-24-211534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.